8 June 2021 - Permits All Eligible Individuals with Late-Onset Pompe Disease Access to AT-GAA Prior to Marketing Authorization in the UK.
Amicus Therapeutics today announced that the UK’s MHRA has granted a positive scientific opinion through the Early Access to Medicines Scheme to AT-GAA, the Company’s investigational two-component therapy for the treatment of Pompe disease.